Navigation Links
Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease
Date:12/9/2009

PROVIDENCE, R.I., Dec. 9 /PRNewswire/ -- The results of a new study on immune-based treatment of Alzheimer's disease (AD), which was conducted at 30 sites around the country, will be published in the December 15 issue of Neurology®. Lead author, Stephen P. Salloway, MD, MS, director of the Butler Hospital Memory and Aging Program and a professor of neurology and psychiatry at the Warren Alpert Medical School of Brown University, says that this 18-month phase two study on slowing the disease process in Alzheimer's patients offers promising results. The study tested the effectiveness of bapineuzumab, which acts like a vaccine to reduce the levels of toxic amyloid protein thought to play a key role in causing Alzheimer's.

"This study was built from the lab up," says Salloway. While many treatments for Alzheimer's disease have been discovered by observing the impact of treatments for other conditions, this treatment is among the first to use what scientists have developed in the lab to treat the underlying cause of the disease. "This study offers a real step forward in our development of effective treatments for Alzheimer's disease," says Salloway.

The results of the study offer an important piece of the Alzheimer's puzzle. What Dr. Salloway and his colleagues found was that the success of this treatment may be influenced by the patient's genetic makeup. Some people have a genetic marker, called the ApoE e4 gene, which makes them more likely to develop Alzheimer's. This gene increases risk and makes it more likely for people to develop the disease at an earlier age. In this study, people who didn't have the gene responded more positively to the treatment.

Sponsored by Elan Pharmaceuticals and Wyeth Research, the study helped to shape a phase three trial that is now in progress. Based on the results of Salloway's phase two trial, the new study will track patients with the ApoE e4 gene separately from those who do not carry the gene, further advancing research on the effectiveness of bapineuzumab.

Affiliated with Brown University's Warren Alpert Medical School's Department of Psychiatry, Butler Hospital is a major research, treatment, and teaching center. For more details on the study results visit neurology.org. More information about Butler Hospital's Alzheimer's and other memory disorders research call 401-455-6265, or visit butler.org.

SOURCE Butler Hospital


'/>"/>
SOURCE Butler Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. George Butler Joins Bionovos Board of Directors
2. Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
3. Xceleron Names Michael Butler as President & CEO
4. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Florida Childrens Hospital and Disney Unite to Create Magical Pediatric Hospital
7. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
8. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
9. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
10. Candid Details on Hospitals Quality of Care Are Now at Your Fingertips - Just Like It Should Be
11. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/9/2017)... SAN FRANCISCO and MOUNTAIN VIEW, ... Zipongo , "Eating Well Made Simple," and 23andMe ... to help guide better food choices.  Zipongo can now ... only their food preferences, health goals and biometrics, but ... to certain food choices. Zipongo,s personalized food ...
Breaking Biology News(10 mins):